Radiobiology and Imaging Program

项目摘要-放射生物学和成像计划（RBI） 放射生物学和成像计划（RBI）旨在促进对以下因素相互作用的理解： 电离和非电离辐射与癌症和正常组织。RBI解决了癌症负担， 通过与我们的社区外展和参与（COE）合作，我们的集水区。科学 目的是：1）开发和表征药物，以改善放射治疗癌症; 2）研究 改变或询问免疫环境以改善治疗效果的放射生物学或成像方法 3）更深入地了解肿瘤微环境（TME）和代谢， 利用这种理解来改善治疗反应; 4）开发新的成像，以最佳地引导 癌症护理;和5）了解质子的生物学效应，以优化其临床使用，并确定 哪些患者将从质子束治疗中受益最大。该计划由Amit Maity，MD，PhD领导， 放射肿瘤学系教授兼执行副主任，以及医学博士丹尼尔·普里马， 放射学副教授兼核医学科主任。梅蒂和普莉玛医生 国家癌症研究所资助的研究人员谁带来了他们的科学视野，这是重点放在基础和 转化研究和开发药物启动的试验。自上次更新以来，该计划 领导者招募了新的初级和高级科学家，加强了同行评审的合作资金，等等 干预性临床试验的应计费用增加了一倍以上，特别是由制药商发起的试验（ 干预性应计项目的91.6%）。Maity和Pryma博士将该计划的重点扩大到成像方式 和治疗诊断学，并进一步加强了RBI中放射生物学和成像之间的整合和相互作用。 一个主要的发展是质子转化和临床研究的实质性扩展， 疗法RBI与其他ACC项目（包括肿瘤生物学，免疫生物学， 癌症治疗，乳腺癌，癌症控制，烟草和环境致癌作用， 儿科肿瘤学。44名项目成员代表宾夕法尼亚大学四所学校的七个部门。RBI 成员拥有1200万美元的研究资助资金（年度直接成本），其中1090万美元用于同行评审， 700万美元是NCI资助的。有654个癌症相关的出版物撰写的计划成员期间， 项目期间。其中，27%是方案内的，35%是方案间的，64%是多方案的。 体制性的。RBI有36个R 01当量。项目成员累积了1,476名受试者参加干预性试验， 3,611例受试者参加了非干预性试验。

PROJECT SUMMARY – Radiobiology and Imaging Program (RBI) The Radiobiology and Imaging Program (RBI) seeks to advance the understanding of the interaction of ionizing and non-ionizing radiation with cancer and normal tissues. RBI addresses the cancer burden within our catchment area through collaboration with our Community Outreach and Engagement (COE). Scientific Aims are to: 1) Develop and characterize agents to improve cancer therapy with radiation; 2) Investigate radiobiological or imaging methods of altering or interrogating the immune environment to improve therapeutic response; 3) Gain a deeper understanding of the tumor microenvironment (TME) and metabolism with the aim to leverage this understanding to improve therapeutic response; 4) Develop novel imaging to optimally guide cancer care; and 5) Understand the biological effects of protons to optimize their clinical use and determine which patients will benefit most from proton beam therapy. The Program is led by Amit Maity, MD, PhD, Professor and Executive Vice-Chair of the Department of Radiation Oncology, and Daniel Pryma, MD, Associate Professor of Radiology and Chief of the Division of Nuclear Medicine. Drs. Maity and Pryma are NCI-funded researchers who bring their scientific vision to this Program, which is focused on basic and translational research and the development of investigator-initiated trials. Since the last renewal, the Program Leaders recruited new junior and senior scientists, enhanced collaborative peer-reviewed funding, and more than doubled accruals to interventional clinical trials, especially investigator-initiated trials (which constitute 91.6% of interventional accruals). Drs. Maity and Pryma expanded the Program's focus on imaging modalities and theranostics and further enhanced the integration and interplay between radiobiology and imaging in RBI. A major development has been the substantial expansion of both translational and clinical studies of proton therapy. RBI has critical interactions with other ACC Programs including Tumor Biology, Immunobiology, Cancer Therapeutics, Breast Cancer, Cancer Control, Tobacco and Environmental Carcinogenesis, and Pediatric Oncology. The 44 Program members represent seven departments from four schools at Penn. RBI members have $12M in research grant funding (annual direct costs), of which $10.9M is peer-reviewed and $7M is NCI-funded. There were 654 cancer-related publications authored by Program members during the project period. Of these, 27% are intra-Programmatic, 35% are inter-Programmatic and 64% are multi- institutional. RBI has 36 R01-equivalents. Program members accrued 1,476 subjects to interventional trials, and 3,611 subjects to non-interventional trials.